Home » Stocks » YMTX

Yumanity Therapeutics, Inc. (YMTX)

Stock Price: $14.80 USD 0.15 (1.02%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $15.48 +0.68 (4.60%) May 7, 4:25 PM
Market Cap 150.87M
Revenue (ttm) 6.90M
Net Income (ttm) -50.79M
Shares Out 2.35M
EPS (ttm) -21.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $14.80
Previous Close $14.65
Change ($) 0.15
Change (%) 1.02%
Day's Open 14.51
Day's Range 14.00 - 15.31
Day's Volume 38,164
52-Week Range 0.94 - 23.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

1 week ago - GlobeNewsWire

YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of Parkinson's disease YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of ...

2 weeks ago - GlobeNewsWire

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative d...

3 weeks ago - GlobeNewsWire

Yumanity Therapeutics (NASDAQ: YMTX) has announced results from preclinical studies of YTX-7739 in glioblastoma multiforme (GBM). Researchers at the Massachusetts General Hospital conducted the study.

1 month ago - Benzinga

YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM

1 month ago - GlobeNewsWire

Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX”

1 month ago - GlobeNewsWire

BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

2 months ago - GlobeNewsWire

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported results from the Phase 1 single ascending dose study in 40-healthy volunteers, evaluating its lead candidate, YTX-7739, an SCD inhibitor, for the treatm...

Other stocks mentioned: PTI
2 months ago - Benzinga

Results reported of the single ascending dose study in healthy volunteers

2 months ago - GlobeNewsWire

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

4 months ago - GlobeNewsWire

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020

4 months ago - GlobeNewsWire

About YMTX

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that... [Read more...]

Industry
Biotechnology
IPO Date
Feb 11, 2016
CEO
Meenu Chhabra
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
YMTX
Full Company Profile

Financial Performance

Financial Statements